Steinbrook, Robert <br/><br/>
Erythropoietin, the FDA, and oncology.  [electronic resource] 

 -  The New England journal of medicine  Jun 2007 
 - 2448-51 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMp078100  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Advisory Committees<br/>Anemia--chemically induced<br/>Darbepoetin alfa<br/>Epoetin Alfa<br/>Erythropoietin--adverse effects<br/>Health Expenditures--trends<br/>Hematinics--adverse effects<br/>Humans<br/>Insurance Coverage--legislation & jurisprudence<br/>Medicare--economics<br/>Neoplasms--complications<br/>Recombinant Proteins<br/>United States<br/>United States Food and Drug Administration